Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma (ESCC) cells via suppression of PI3K/AKT and Stat3 pathways.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Archives of Biochemistry and Biophysics

• Publication date

  2015-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.abb.2014.11.008PMID 25843419
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines.

  2014cited by this paper
• Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy.

  2014cited by this paper
• Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.

  2013cited by this paper
• Antitumor effects of Dasatinib on laryngeal squamous cell carcinoma in vivo and in vitro

  2013cited by this paper
• ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin

  2013cited by this paper
• miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.

  2013cited by this paper
• BRCA1 mRNA Expression as a Predictive and Prognostic Marker in Advanced Esophageal Squamous Cell Carcinoma Treated with Cisplatin- or Docetaxel-Based Chemotherapy/Chemoradiotherapy

  2013cited by this paper
• Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.

  2012cited by this paper
• Retinoblastoma: Epigenetic outcome

  2012cited by this paper
• Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.

  2012cited by this paper
• Mind the gap; regulation of gap junctional, intercellular communication by the SRC oncogene product and its effectors.

  2012cited by this paper
• Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.

  2012cited by this paper
• Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway

  2011cited by this paper
• Phase II Trial of Docetaxel and Carboplatin in Patients With Advanced Squamous Carcinoma of the Esophagus (E2298): A Trial of the Eastern Cooperative Oncology Group.

  2011cited by this paper
• c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.

  2010cited by this paper
• Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: implication of c-Src and its inhibitor.

  2009cited by this paper
• Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin

  2009cited by this paper
• Akt1 inhibition by RNA interference sensitizes human non‐small cell lung cancer cells to cisplatin

  2008cited by this paper
• ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells.

  2007cited by this paper
• p53 tumor suppressor protein regulates the levels of huntingtin gene expression

  2006cited by this paper
• Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

  2006cited by this paper
• Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.

  2006cited by this paper
• The interplay between Src family kinases and receptor tyrosine kinases

  2004cited by this paper
• A renaissance for SRC

  2004cited by this paper
• Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein.

  1995cited by this paper
• Effect of anticancer drugs and desferrioxamine in combination with radiation on hepatoma cell lines.

  1993cited by this paper

• Curcuminoid based novel chiral Pt-Corates: Supramolecular combinatorial chemotherapeutic system

  2025cites this paper
• YAP as a therapeutic target in esophageal squamous cell carcinoma: insights and strategies

  2025cites this paper
• Harnessing Single-Cell RNA-Seq for Computational Drug Repurposing in Cancer Immunotherapy

  2025cites this paper
• Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes

  2025cites this paper
• Cuproptosis/OXPHOS Tendency Prediction of Prognosis and Immune Microenvironment of Esophageal Squamous Cell Carcinoma: Bioinformatics Analysis and Experimental Validation.

  2024cites this paper
• PI3K/AKT and STAT3 pathways mediate the neuroprotective effect of dasatinib from acute cerebral injury in endotoxemic mice

  2024cites this paper
• Multiaction Pt(IV) Prodrugs Releasing Cisplatin and Dasatinib Are Potent Anticancer and Anti-Invasive Agents Displaying Synergism between the Two Drugs.

  2024cites this paper
• Co-assembly of cisplatin and dasatinib in hyaluronan nanogel to combat triple negative breast cancer with reduced side effects.

  2024cites this paper
• Molecular mechanism, regulation, and therapeutic targeting of the STAT3 signaling pathway in esophageal cancer (Review)

  2022cites this paper
• Src inhibitor dasatinib sensitized gastric cancer cells to cisplatin

  2022cites this paper
• Drug repositioning for esophageal squamous cell carcinoma

  2022cites this paper
• Role of PI3K/AKT pathway in squamous cell carcinoma with an especial focus on head and neck cancers

  2022cites this paper
• Development and Validation of a Ferroptosis-Related Gene Signature and Nomogram for Predicting the Prognosis of Esophageal Squamous Cell Carcinoma

  2021cites this paper
• Carrier-free prodrug nanoparticles based on dasatinib and cisplatin for efficient antitumor in vivo

  2021cites this paper
• Evidence of Omics, Immune Infiltration, and Pharmacogenomic for SENP1 in the Pan-Cancer Cohort

  2021cites this paper
• Cancer-derived IgG involved in cisplatin resistance through PTP-BAS/Src/PDK1/AKT signaling pathway.

  2020cites this paper
• BRE Promotes Esophageal Squamous Cell Carcinoma Growth by Activating AKT Signaling

  2020cites this paper
• miR-139-5p enhances cisplatin sensitivity in non-small cell lung cancer cells by inhibiting cell proliferation and promoting apoptosis via the targeting of Homeobox protein Hox-B2

  2020cites this paper
• Identification of hub genes and therapeutic drugs in esophageal squamous cell carcinoma based on integrated bioinformatics strategy

  2019cites this paper
• Second-generation Src/Abl inhibitor bosutinib effectively induces apoptosis in human esophageal squamous cell carcinoma (ESCC) cells via inhibiting Src/Abl signaling.

  2019cites this paper
• Targeting Upstream Kinases of STAT3 in Human Medulloblastoma cells.

  2019cites this paper
• Focal adhesion kinase activation limits efficacy of Dasatinib in c‐Myc driven hepatocellular carcinoma

  2018cites this paper
• BAG2 Overexpression Correlates with Growth and Poor Prognosis of Esophageal Squamous Cell Carcinoma

  2018cites this paper
• ANXA2 promotes esophageal cancer progression by activating MYC-HIF1A-VEGF axis

  2018cites this paper
• Metformin inhibits the proliferation and metastasis of osteosarcoma cells by suppressing the phosphorylation of Akt.

  2018cites this paper
• Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma

  2018cites this paper
• Identification of the key transcription factors in esophageal squamous cell carcinoma.

  2018cites this paper
• Overview of Transcription Factors in Esophagus Cancer

  2017cites this paper
• Differentially activated Src kinase in chemo‐naïve human primary osteosarcoma cells and effects of a Src kinase inhibitor

  2017cites this paper
• PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma

  2017cites this paper
• Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines

  2016cites this paper
• eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma

  2016cites this paper
• RUNX3 reverses cisplatin resistance in esophageal squamous cell carcinoma via suppression of the protein kinase B pathway

  2016cites this paper
• Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma

  2016cites this paper
• Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation

  2016influential citation
• Inhibitors of Upstream Inducers of STAT Activation

  2016cites this paper
• A Mechanism for the Temporal Potentiation of Genipin to the Cytotoxicity of Cisplatin in Colon Cancer Cells

  2016cites this paper
• Plasticity of Cancer Cell Invasion-Mechanisms and Implications for Therapy.

  2016cites this paper
• BAG 2 overexpression correlates with growth and poor prognosis of esophageal squamous cell carcinoma

  year unknowncites this paper
• STMN 1 , a prognostic predictor of esophageal squamous cell carcinoma , is a marker of the activation of the PI 3 K pathway

  year unknowncites this paper
• Oncotargets and Therapy Dovepress Dovepress Clinicopathological Significance of Stat4 in Hepatocellular Carcinoma and Its Effect on Cell Growth and Apoptosis

  year unknowncites this paper